Applied Therapeutics Forum: Community User: Reevo90

Applied Therapeutics (Nasdaq: APLT) agreed to be acquired by Cycle Group Holdings for $0.088 per share cash plus one non-transferrable contingent value right (CVR). The CVR can pay up to $0.10 for FDA approval in a galactosemia indication, $0.10 for FDA approval in CMT-SORD, and $0.20 upon first worldwide net sales ≥ $200M in any four-quarter period; CVR holders also share in a capped Closing Cash Payment tied to Applied cash above $500,000 (capped at $1.5M). The tender offer is expected to close in Q1 2026; the merger has no financing condition. Applied received an unsecured promissory note enabling up to $8.5M in loans to fund working capital.